

PRESS RELEASE

SUVEN LIFE SCIENCES NET INCOME UP BY 27.76% ; SPENDS 20.41% OF REVENUES FOR R&D

Suven's total income for the 12 months ending 31st March, 04 stood at Rs. 5171.98 lacs as compared to Rs. 4699.09 lacs for the corresponding period of previous year, recording a growth of 10%, in spite of 36.35% reduction in 4th quarter income. Income for the 4th quarter stood at Rs. 1096.04 lacs as compared to Rs. 1722.24 lacs for the corresponding previous period. Export revenue in the current year marked a growth of 13%, increased from Rs. 3103.15 lacs to Rs. 3513.90 lacs.

For the 4th quarter ending March, 04, PBT is Rs. 115.25 lacs and PAT stood at Rs. 39.82 lacs, a huge fluctuation which is inherent to C-R-A-M-S model.

For the year ending March, 04, PBT is Rs. 1031.64 lacs registering a growth of 6.64% and the PAT stood at Rs. 719.31 lacs which increased by 27.76% while compared to the previous year.

The notable feature for the year is Suven's continuous thrust on research and development. During the year, in its endeavour to offer entire spectrum of services from Drug discovery through manufacturing, Suven continues to deploy funds in R&D amounting to Rs.1058.76 lacs constituting 20.41% of the total income.

During the year the Company's shares face value of Rs.10.00 each were subdivided into face value of Rs.2.00 each, the same being listed at Bombay Stock Exchange, National Stock Exchange and Hyderabad Stock Exchange with the record date of 23rd Jan, 04.

The basic and diluted EPS on expanded capital is Rs. 3.18 per share (previous year Rs. 2.56) of face value of Rs. 2/- each, recording an increase by 24% over the previous year.

I>